Tissue Kinetics

On account of its favourable pharmacokinetic properties, such as the high volume of distribution (Vdss), Baytril reaches and maintains high concentrations in target tissues, body fluids and secretions. In general, tissue concentrations significantly exceed those of plasma.

Most of the data represent values measured in healthy animals. There is evidence that drug concentrations are significantly higher when an inflammatory reaction is present in the tissues.

Results from a recent clinical study, where enrofloxacin skin concentrations of healthy dogs are compared with those of dogs suffering from pyoderma show that enrofloxacin concentrations in inflamed skin are nearly 2 times higher, compared to healthy skin (6).

PDF Version (Size: 603 KB) © 2001 Bayer AG

References
(6) DeManuelle TC, Ihrke PJ, Vulliet PR: Comparison of enrofloxacin skin concentrations in normal dogs and in dogs with pyoderma. Suppl Compend Contin Educ Pract Vet 21 (12): 49-56, 1999.
(10) Hawkins EC, Boothe DM, Guinn A, Aucoin DP, Nguyen J: Concentration of enrofloxacin and its active metabolite in alveolar macrophages and pulmonary epithelial lining fluid of dogs. J vet Pharmacol Therap 21: 18-23, 1998.
(16) Scheer M: Concentrations of active ingredient in the serum and in tissues after oral and parenteral administration of Baytril. Vet Med Rev 2: 104-118, 1987.
(17) Scheer M, Stegemann M: Vergleich der Serumspiegel bei Hunden nach oraler, subkutaner und intravenöser Baytril®-Applikation; Sekretionsspiegel des Baytril® im Speichel bei Hunden. Proceedings WSAVA + FKDVG Kongreß Berlin: 437, 1993.
(18) Dorfman M, Barsanti J, Budsberg SC: Enrofloxacin concentrations in dogs with normal prostate and dogs with chronic bacterial prostatitis. Am J Vet Res 56 (3): 386-390, 1995.
(19) Boeckh A, Boothe DM, Wilkie S: Time course of enrofloxacin and its active metabolite in peripheral leucocytes of dogs. Suppl. Compend. Contin. Educ. Pract Vet 21 (12): 40-43, 1999.